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ABSTRACT
Objective: European cancer survival rates vary widely. System factors, including whether or not
primary care physicians (PCPs) are gatekeepers, may account for some of these differences. This
study explores where patients who may have cancer are likely to present for medical care in dif-
ferent European countries, and how probability of presentation to a primary care clinician corre-
lates with cancer survival rates.
Design: Seventy-eight PCPs in a range of European countries assessed four vignettes represent-
ing patients who might have cancer, and consensus groups agreed how likely those patients
were to present to different clinicians in their own countries. These data were compared with
national cancer survival rates.
Setting: A total of 14 countries.
Subjects: Consensus groups of PCPs.
Main outcome measures: Probability of initial presentation to a PCP for four clinical vignettes.
Results: There was no significant correlation between overall national 1-year relative cancer sur-
vival rates and the probability of initial presentation to a PCP (r ¼0.16, 95% CI0.39 to 0.08).
Within that there was large variation depending on the type of cancer, with a significantly
poorer lung cancer survival in countries where patients were more likely to initially consult a
PCP (lung r¼0.57, 95% CI0.83 to0.12; ovary: r¼0.13, 95% CI0.57 to 0.38; breast
r¼ 0.14, 95% CI0.36 to 0.58; bowel: r¼ 0.20, 95% CI0.31 to 0.62).
Conclusions: There were wide variations in the degree of gatekeeping between countries, with
no simple binary model as to whether or not a country has a “PCP-as-gatekeeper” system. While
there was case-by-case variation, there was no overall evidence of a link between a higher prob-
ability of initial consultation with a PCP and poorer cancer survival.
KEY POINTS
 European cancer survival rates vary widely, and health system factors may account for some
of these differences.
 The data from 14 European countries show a wide variation in the probability of initial pres-
entation to a PCP.
 The degree to which PCPs act as gatekeepers varies considerably from country to country.
 There is no overall evidence of a link between a higher probability of initial presentation to a
PCP and poorer cancer survival.
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Introduction
There is wide variation in the cancer survival rates
across Europe [1,2]. For example, in the United
Kingdom, over 6000 deaths a year that occurred within
5 years of diagnosis would have been avoided if
survival in Britain had matched the mean for Europe
[3,4], representing 6–7% of all deaths due to cancer.
The variation in European 1-year relative cancer survival
rates is even higher than that for 5-year survival. While
1-year relative survival rates for cancer can be affected
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by lead-time and over-diagnosis biases [5,6], they are
generally taken to be an indicator of more advanced
disease at diagnosis [4,7]. Analysis of the EUROCARE-5
data [8] shows that the 1-year relative survival rate for
all cancer sites varies from 60.0 to 80.5% between regis-
tries, with large variation even within EUROCARE’s five
main European regions. Some studies have suggested
that there are also differences between countries in
cancer stage at the time of starting treatment [9–11].
The survival and stage differences raise the question as
to how much the differing diagnostic pathways in
those countries affect the speed of diagnosis.
While recent overall cancer survival trends show
improvement [12], there is little narrowing in the
national differences [13].
Healthcare systems considered to have a primary
care gatekeeper system tend to have a significantly
lower 1-year relative cancer survival than systems with-
out such gatekeeper functions [14]. However, achieving
more timely cancer diagnoses in primary care poses a
considerable challenge [15]. A primary care physician
(PCP) will see only a small number of new cancers each
year. Half of patients with malignancies present in pri-
mary care with evolving and undifferentiated symp-
toms [16] that are much more likely to be interpreted
as something other than cancer. Even classical “red
flag” symptoms like dysphagia and rectal bleeding have
positive predictive values of less than 6% [17].
The €Oren€as Research Group is a collaborative group
of researchers from 20 European countries that investi-
gates how primary care factors influence the varying
European cancer survival rates. Discussion within the
group suggested that, in some countries that are con-
sidered to have PCPs as gatekeepers, some patients
bypass the PCP. Conversely, in other countries where
patients can consult specialists without PCP referral, the
majority of adult patients still present to PCPs. In add-
ition, a previous study shows that there can be different
levels of gatekeeping, for instance with some PCPs
being gatekeepers for all patients except for children, or
women with gynaecological problems [18]. This study
was therefore designed to find out where patients with
possible cancer symptoms are likely to present in differ-
ent European countries, and how that correlates with
national 1-year relative cancer survival rates.
Material and methods
Study design
The study used a case-based questionnaire, completed
by consensus groups from 14 European countries.
Four vignettes were included in the questionnaire.
Each of these vignettes gave the patient’s presenting
symptoms, previous medical history, medication, clin-
ical findings and other relevant information. Two of
the vignettes were designed and validated by the
International Cancer Benchmarking Partnership (ICBP)
[19], and used with permission. Minor changes were
made to make the vignettes relevant to the study for-
mat, which was designed by eight members of the
€Oren€as Research Group. This group also piloted
the questionnaire with local colleagues. The clinical
scenarios were written in English and placed in an on-
line questionnaire. All participants used this single
questionnaire.
The vignettes were:
1. A 62-year-old male smoker with chronic obstruct-
ive pulmonary disease who now has a two-week
history of a productive cough, positive predictive
value for lung cancer (PPV): 3.6% [20];
2. A 53-year-old woman with lower abdominal pain
and abdominal distension, PPV for ovarian cancer:
3.1% [21];
3. A 35-year-old breastfeeding woman with an
abnormal nipple discharge and eczematous
changes around the nipple, PPV for breast cancer
below 1.2% [22];
4. A 22-year-old man with coeliac disease who now
has abdominal pain, rectal bleeding and diarrhea
(no evidence to estimate PPV for colorectal cancer
available).
Respondents were asked to agree the probability
that each patient would initially present to each of the
following:
 A PCP/general practitioner;
 A practice nurse (i.e. a nurse working in a primary
care practice);
 A specialist doctor outside a hospital;
 A specialist doctor in a hospital;
 A specialist nurse outside a hospital;
 A specialist nurse in a hospital;
 A hospital emergency department.
For each vignette there was also space for free-text
entries.
Selection of study subjects and information
gathering
As PCPs were thought to have the best overview of
where patients may initially present, the €Oren€as
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Research Group lead in each centre invited local key
informant PCPs to join a consensus group. During the
consensus group meetings, members were asked to
complete the questionnaire individually, then the
results were pooled and discussed until a group con-
sensus was achieved for each vignette. Each of the
local leads entered their consensus group’s responses
into an on-line survey questionnaire. MH downloaded
and analysed the survey results.
Outcomes and analysis
For each centre, the probability of presentation of
each vignette to each type of clinician was noted. The
mean probabilities were then calculated for each of
the clinicians that were considered in the question-
naire, as well as for each of the four vignettes.
Probability values for PCP/practice nurse, specialist
doctor inside/outside hospital and specialist nurse
inside/outside hospital pairs were added together to
give composite values for each. Three countries each
had €Oren€as leads in two different regional centres; for
these, the mean probability values for each pair of
centres were used. Data on national 1-year relative
survival for each of the four cancers were downloaded
from the EUROCARE-5 database [8]. Pearson’s correl-
ation coefficients for each set of probabilities with
their national 1-year relative survival rates were then
calculated.
Results
Study population
€Oren€as Research Group members from 17 centres in 14
countries completed the on-line survey (Table 1). These
included at least three countries in each of Central,
Eastern, Northern and Southern Europe. The countries
represented ranged from those with the highest
EUROCARE-5 1-year cancer relative survival ranking to
those with the lowest, and there were at least three
countries in each survival quartile [8,12]. Some
responses related to regions and others to whole coun-
tries. A total of 78 clinicians participated, with a median
of four (range 3–9) in each consensus group.
Outcomes of the study
Table 2 shows the mean probability of presentation to
each type of clinician for each participating country.
The probabilities of presentation to each clinician
group are given in Table 3 and the range of variations
is summarised in Figure 1. The median overall prob-
ability across all the surveyed countries of initial pres-
entation to a primary care clinician (a PCP or a
practice nurse) was 0.48, though with a wide variation
(range 0.28–0.95). Patients were less likely to present
directly to specialist physicians than to PCPs, but again
with a wide variation (median probability ¼ 0.24,
range 0–0.47). There was a low overall probability of
initial consultation with a specialist nurse in all the
countries studied (median probability ¼ 0.08, range
0–0.13), but a wider variation in the probability of an
initial presentation at an emergency department
(median probability ¼ 0.12, range 0–0.25).
Table 3 also shows the correlations between the
probability of initial presentation to each clinician
group and each country’s 1-year overall relative cancer
survival. For primary care clinicians and specialist
physicians there was no significant correlation.
However, there was a significant positive correlation
for probability of presentation to a specialist nurse,
and a significant negative correlation for probability of
presentation to an emergency department.
Table 1. List of participating consensus groups, with national 1-year relative cancer survival rates.
Country Region represented in survey
Number of clinicians
in consensus group
EUROCARE-5 national 1-year relative
survival rate for all adult cancers (%)
Bulgaria Plovdiv 9 60.0
Croatia Primorsko-goranska county 4 63.8
Denmark Denmark 5 69.9
England The West of England 4 66.9
France North of Paris and northern suburb of Paris 7 78.2
Germany North Rhine-Westphalia 3 77.3
Mittelhessen 3
Italy Caserta, Southern Italy 3 74.1
Norway Norway 3 75.5
Poland Białystok-Podlasie 5 63.8
Kujawsko-Pomorskie 4
Scotland Northeast of Scotland 3 64.4
Slovenia Central region 4 69.3
Spain Mallorca 7 71.5
Barcelona 3
Sweden Sweden 7 80.5
Switzerland Kanton Bern 4 78.4
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Table 2. Mean probability of presentation to each clinician for each participating country.
A primary care
physician/
family doctor
A practice nurse
(a nurse working
in a primary
care practice)
A specialist
doctor outside a
hospital
A specialist
doctor in a
hospital
A specialist
nurse outside a
hospital
A specialist
nurse in a
hospital
A hospital
emergency
department Another clinician
Bulgariaa 0.43 0.00 0.20 0.13 0.00 0.00 0.14 0.10
Croatiab 0.47 0.00 0.15 0.06 0.00 0.00 0.23 0.09
Denmark 0.95 0.00 0.00 0.05 0.00 0.00 0.00 0.00
Englandc 0.39 0.17 0.00 0.00 0.09 0.00 0.23 0.12
Franced 0.39 0.00 0.16 0.08 0.04 0.02 0.13 0.19
Germanye 0.36 0.00 0.32 0.05 0.10 0.01 0.11 0.05
Italy 0.58 0.00 0.21 0.19 0.00 0.00 0.03 0.00
Norwayf 0.56 0.00 0.15 0.00 0.06 0.06 0.00 0.18
Polandg 0.39 0.03 0.29 0.10 0.07 0.00 0.11 0.00
Scotland 0.40 0.30 0.00 0.00 0.09 0.00 0.20 0.00
Sloveniah 0.48 0.03 0.17 0.03 0.08 0.00 0.06 0.16
Spaini 0.37 0.05 0.09 0.04 0.04 0.03 0.24 0.14
Swedenj 0.47 0.14 0.11 0.05 0.07 0.03 0.02 0.11
Switzerland 0.43 0.05 0.28 0.06 0.00 0.00 0.19 0.00
aBulgaria: Patients with COPD are under the surveillance of chest specialists, allowing direct access; neither nurses nor midwives are able to diagnose or
prescribe; some PCPs are qualified in internal medicine, but few are qualified in gynaecology.
bCroatia: Some patients present directly to a primary care emergency department.
cEngland: Some patients present directly to heath visitor, or to a primary care emergency department.
dFrance does not have practice nurse or specialist nurse systems; the PMI (Protection Maternal et Infantile) system is responsible for prevention of mater-
nal problems.
eGermany does not have practice nurse or specialist nurse systems; probability of presentation to a specialist depends on waiting times (higher probabil-
ity if shorter waiting time).
fNorway: Some patients present directly to a primary care emergency department.
gIn Poland, COPD and some other chronic conditions are usually managed by specialists. However, if the waiting time for a specialist is longer, a patient
is more likely to see a PCP.
hSlovenia: Patients may be seen in a primary care emergency department.
iSpain: There is regional variation in the proportion of patients who first present to a specialist.
jIn Sweden, a 24-hour-a-day health hotline may be the initial point of contact.
Table 3. Probability of presentation to each clinician group for all four vignettes combined and correl-
ation between the probability of initial presentation to each clinician group and each country’s 1-year
overall relative cancer survival.
Clinician group Probability of presentation (range) Pearson’s correlation coefficient (95% CI)
Primary care clinician 0.48 (0.28–0.95) 0.16 (0.39, 0.08)
Specialist doctor 0.24 (0–0.47) 0.04 (0.27, 0.20)
Specialist nurse 0.08 (0–0.13) 0.45a (0.23, 0.62)
Emergency department 0.12 (0–0.25) 0.33a (0.53, 0.10)
ap< 0.05.
Probability 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
Primary care
clinician
Specialist doctor Specialist nurse Hospital emergency
department
Figure 1. Box and whisker plot of overall probability of presentation to each clinician group.
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Table 4 shows, for each individual vignette, the cor-
relation between the probability of initial presentation
to each clinician group and that country’s individual
cancer 1-year relative cancer survival. It is shown
graphically for primary care clinicians in Figure 2. For
the patient with possible lung cancer, there was a sig-
nificant negative correlation between the probability
of initial presentation to a primary care clinician and
each country’s 1-year relative lung cancer survival rate.
This compared with a significant positive correlation
between survival and the probability of initial presen-
tation to a specialist physician. There was no signifi-
cant correlation with the probability of initial
presentation to a specialist nurse or an emergency
department.
For the patient with possible ovarian cancer, there
was a very small, non-significant negative correlation
with 1-year relative ovarian cancer survival rates for
presentation to a primary care clinician, and a negli-
gible correlation with the probability of initial presen-
tation to a specialist physician. While there was only a
probability of presentation to a nurse specialist in
three countries, this was associated with an improved,
but not statistically significant, 1-year relative survival.
For presentation to an emergency department there
was a reasonably large, but non-significant, negative
correlation.
For the vignette with possible breast cancer, there
were no significant correlations between national
1-year relative breast cancer survival rates and the prob-
abilities of initial presentation for any of the clinician
groups. Similarly, for the patient with possible colorec-
tal cancer, there were no significant correlations.
Discussion
Statement of principal findings
The data from this primary care-based vignette
study show a wide variation in the probability of
initial presentation to a primary care clinician (a PCP
or a practice nurse). The data show no significant
overall evidence of a link between consensus group
estimates of higher probability of initial presentation
to a primary care clinician and altered cancer sur-
vival. However, there was case-by-case variation,
with a significantly poorer lung cancer survival in
countries where patients are more likely to initially
consult a PCP.
Table 4. Correlations, for individual vignettes, between probability of initial presentation to each clinician group and national
cancer 1-year relative cancer survival.
Pearson’s correlation coefficient (95% CI) for each clinician group
Vignette Primary care clinician Specialist doctor Specialist nurse Emergency department
Possible lung cancer 0.57a (0.83, 0.12) 0.55a (0.09, 0.81) 0.28 (0.67 to 0.24) 0.06 (0.43, 0.53)
Possible ovarian cancer 0.13 (0.57, 0.38) 0.08 (0.42, 0.54) 0.40 (0.10, 0.74) 0.46 (0.77, 0.03)
Possible breast cancer 0.14 (0.36, 0.58) 0.13 (0.57, 0.38) 0.11 (0.39, 0.66) 0.06 (0.53, 0.43)
Possible colorectal cancer 0.20 (0.31 to 0.62) 0.04 (0.51 to 0.45) 0.11 (0.56, 0.39) 0.13 (0.57, 0.37)
ap< 0.05.
-1.0
-0.8
-0.6
-0.4
-0.2
0.0
0.2
0.4
0.6
0.8
Lung cancer
vignette
Ovarian cancer
vignette
Breast cancer
vignette
Colorectal cancer
vignette
r value 
Figure 2. Correlations for individual vignettes between probability of initial presentation to a primary care clinician and national
1-year relative cancer survival rates, with 95% confidence intervals.
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Strengths and weaknesses of the study
The study gathered data from 17 primary care
research centres in 14 European countries, with at
least three centres in each of Eastern, Southern,
Northern and Central Europe. All centres used an iden-
tical set of vignettes and questions.
While the use of consensus groups is a recognised
methodology for probability estimations [23], there
may have been bias in consensus group membership
selection, and a special interest in cancer survival rates
may itself have caused bias. The PCPs in the groups
may have had an inaccurate view of where patients in
their jurisdictions were likely to present. However,
recent real-life data on the route that patients take
through the UK healthcare system before receiving a
cancer diagnosis [24,25] show results that are similar
to the consensus findings in our study. While the con-
sensus groups were small, there is evidence that small
group size maximises decision accuracy [26], and that
the degree of consensus increases with decreasing
group size [27].
The questionnaire used a Likert scale to report the
probability of initial presentation to a clinician, but
these probabilities were estimates by the consensus
groups: participants from different centres may have
interpreted the task differently because of differences
in their cultural values and languages, and they may
have had other social or health system factors, such as
national levels of healthcare spending [28], that acted
as confounders. Not all European countries were
included in the survey, and there may have been a
type II error, i.e. the study may have been underpow-
ered to detect small significant differences. The
EUROCARE-5 survival rate data may have been
affected by information bias. While the questionnaire
gave “PCP” and “Internal medicine specialist” as separ-
ate options, some PCPs are also qualified as internal
medicine specialists in some of the countries repre-
sented. However, each clinical scenario also gave a
free-text entry option to allow participants to identify
and comment on these issues.
Findings in relation to other studies
This study suggests that the “PCP as gate-keeper”
model does not necessarily map across to how
patients initially seek help, and in some of the coun-
tries where PCPs do not have a gatekeeper function,
more than half of presentations are still likely to be to
a primary care clinician. A recent ICBP study demon-
strated a correlation between the readiness of primary
care practitioners to investigate symptoms indicative
of cancer and improved cancer survival rates [29], and
the way in which different healthcare systems support
primary care in cancer diagnosis by quick and easy
access to investigations may be a factor in speed of
cancer diagnosis [30]. There has been a call for better
understanding of interactions between health system
factors and professional behaviour, so that outcomes
can be improved [31]. Two recent studies suggest that
there is a relationship between the medical system
and physicians’ readiness and opportunity to refer
based on a suspicion [29,31]. Many non-clinical factors
are likely to have a significant impact on referral deci-
sions; these include levels of gatekeeping responsibil-
ity, funding systems, access to special investigations,
fear of litigation, and relationships with specialist col-
leagues [18]. It may also be that a formal gatekeeping
system introduces an asymmetrical relationship
between the patient and the PCP which can result in
patients self-restricting their care-seeking [32], whereas
the knowledge that a patient can, if wished, independ-
ently seek specialist advice may affect both patients’
and PCPs’ decision-making.
Our finding of a link between the probability of
presentation to a primary care clinician and poorer
survival for patients who may have lung cancer could
be due to a variety of factors. It may be that primary
care clinicians have poorer access to X-ray facilities
than their specialist colleagues, and there is evidence
that lung cancer patients presenting to hospital in the
UK without a suspicious chest X-ray are less likely to
have specialist care or histological confirmation of
their cancer, and they have lower rates of active treat-
ment [33]. There is also evidence that, where a chest
X-ray for a patient with lung cancer does originate in
primary care, there is an earlier stage at diagnosis [34].
There may be confounding factors: for instance,
inequality in the treatment given to lung cancer
patients could be due to variations in access to oncol-
ogy services, with evidence for longer survival in
patients whose first hospital attendance is at a radio-
therapy centre [35]. Also, there is a significant variation
between the lung cancer referral guidelines in differ-
ent jurisdictions [36].
While this study showed a significant positive cor-
relation between overall cancer survival rates and like-
lihood of initial consultation with a specialist nurse,
that likelihood was low in all countries, so the import-
ance of this link is unclear. However, while the role
and competencies of specialist nurses are diverse
across Europe [37], it is thought that they have know-
ledge of, and insight into, the entire patient pathway,
as well as high levels expertise for the patient groups
for which they care [37,38].
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It is known that patients with cancer who present
as an emergency experience higher short-term mortal-
ity compared with non-emergency presentations, even
when age, stage, and co-morbidity are accounted for
[39,40]. This was reflected in our finding of a signifi-
cant negative correlation between probability of an
initial presentation at an emergency department and
national 1-year relative cancer survival rates. Higher
levels of emergency department cancer presentations
could be due to delayed recognition of sinister symp-
toms by patients or their physicians, unavailability of
non-emergency routes to care, or a complex inter-
action between these [41], while lower levels of pres-
entation to emergency departments may indicate
good quality of cancer care in general [42].
Implications for clinical policy and research
The ICBP study [29] found a link between the readi-
ness of primary care practitioners to investigate symp-
toms indicative of cancer and cancer survival rates,
but found no specific health system features that con-
sistently explained these findings. While it has been
suggested that countries with a gatekeeper system
have a significantly lower 1-year relative cancer sur-
vival than systems without such gatekeeper functions
[14], our study identified wide variations in the degree
of gatekeeping between countries, with no simple bin-
ary model as to whether or not a country has a
“PCP-as-gatekeeper” system. Further research on how
system factors affect cancer survival rates is needed.
Conclusion
This vignette-based study provides information on
how patients who may have cancer are likely to seek
help initially, how that varies across 14 European
countries, and how it relates to 1-year relative cancer
survival rates. Although there was case-by-case vari-
ation, we found no overall evidence of a link between
a higher probability of initial presentation to a primary
care clinician and altered cancer survival.
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